Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16953047 | 0.85 | CA2 (0.41) | HSD11B1ALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL2000756 | 0.82 | HSD11B1 (0.46) | HSD11B1ALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL646458 | 0.81 | HSD11B1 (0.49) | HSD11B1ALDH1A1POLBTDP1L3MBTL1 | |
| Lithium SCHEMBL5691154 | 0.79 | HSD11B1 (0.44) | HSD11B1ALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL3244584 | 0.78 | HSD11B1 (0.30) | HSD11B1 | |
| SCHEMBL67468 | 0.77 | ALDH1A1 (0.43) | HSD11B1ALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL5254379 | 0.77 | KIF11 (0.33) | HSD11B1ALDH1A1POLBAXLKIF11 | |
| SCHEMBL476648 | 0.76 | MPL (0.40) | HSD11B1ALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL6067687 | 0.75 | HSD11B1 (0.55) | HSD11B1ALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL16951150 | 0.74 | NOTUM (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109776553-A | Own element of good fortune and its preparation method and application | 山东师范大学 | 2019-05-21 | — | — | CN | claimed |
| CN-109678872-A | Bisbenzylisoquinolincompounds compounds and its preparation method and application | 山东师范大学 | 2019-04-26 | — | — | CN | claimed |
| US-20090176799-A1 | PHOSPHODIESTERASE 4 INHIBITORS | RUIPING LIU | 2009-07-09 | — | — | US | claimed |
| US-20050272803-A1 | Phosphodiesterase 4 inhibitors | RUIPING LIU | 2005-12-08 | — | — | US | claimed |
| EP-1435944-A1 | 4(4-ALKOXY-3-HYDROXYPHENYL)-2-PYRROLIDONE DERIVATIVES AS PDE-4 INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL SYNDROMES | Memory Pharmaceutical Corporation (US) | 2004-07-14 | — | — | EP | claimed |
| EP-1194428-B1 | HETEROARYL PROTEASE INHIBITORS AND DIAGNOSTIC IMAGING AGENTS | DIMENSIONAL PHARM INC (US) | 2003-09-17 | — | — | EP | claimed |
| US-20030139406-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2003-07-24 | — | — | US | claimed |
| WO-2003032981-A1 | 4-(4-ALKOXY-3-HYDROXYPHENYL)-2-PYRROLIDONE DERIVATIVES AS PDE-4 INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL SYNDROMES | MEMORY PHARMACEUTICALS CORPORATION (US) | 2003-04-24 | — | — | WO | claimed |
| US-6420397-B1 | Heteroaryl protease inhibitors and diagnostic imaging agents | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-07-16 | — | — | US | claimed |
| EP-1194428-A1 | HETEROARYL PROTEASE INHIBITORS AND DIAGNOSTIC IMAGING AGENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-04-10 | — | — | EP | claimed |
| WO-2001004117-A1 | HETEROARYL PROTEASE INHIBITORS AND DIAGNOSTIC IMAGING AGENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-01-18 | — | — | WO | claimed |
| EP-0778284-A2 | New 7-beta-substituted-4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors | MERCK & CO. INC. (US) | 1997-06-11 | — | — | EP | claimed |
| EP-0572166-A1 | New 7beta-substituted-4-aza-5a-androstan-3-ones as 5a-reductase inhibitors | MERCK & CO. INC. (US) | 1993-12-01 | — | — | EP | claimed |
| WO-1993023039-A1 | SUBSTITUTED 4-AZA-5A-ANDROSTAN-ONES AS 5A-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | claimed |
| WO-1993023420-A1 | NEW 7β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | claimed |
| US-12023371-B2 | Terminally modified RNA | MODERNATX, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2024-05-23 | — | — | US | disclosed |
| WO-1999026926-A1 | HETEROARYL AMINOGUANIDINES AND ALKOXYGUANIDINES AND THEIR USE AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| US-5811834-A | Light-emitting material for organo-electroluminescence device and organo-electroluminescence device for which the light-emitting material is adapted | TOYO INK MANUFACTURING CO., LTD. (JP) | 1998-09-22 | — | — | US | disclosed |
| EP-0786926-A2 | Light-emitting material for organo-electroluminescence device and organo-electroluminescence devive for which the light-emitting material is adapted | TOYO INK MANUFACTURING CO., LTD. (JP) | 1997-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139406-A1 | Phosphodiesterase 4 inhibitors | PDE12, PDE4A, PDE5A | HSD11B1 137/4885ALDH1A1 106/4885POLB 2842/4885 |
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | HSD11B1 4781/4885ALDH1A1 1969/4885POLB 37/4885 |
| US-20090176799-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE12, PDE3B | HSD11B1 187/4885ALDH1A1 132/4885POLB 3029/4885 |
| US-12023371-B2 | Terminally modified RNA | RNGTT, NSUN3, RNMT | HSD11B1 4486/4885ALDH1A1 4235/4885POLB 511/4885 |
| US-20050272803-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE12, PDE3B | HSD11B1 187/4885ALDH1A1 132/4885POLB 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.